-

News & Events

  • Share Share this page

Section Contents Menu

-

Review of the ReGen Menaflex

Preliminary findings and recommendations regarding FDA's review and clearance of ReGen Biologics Inc.'s submission to market a device for use in treating injuries to the meniscus (knee cartilage).


Transcript for FDA's Media Briefing on the FDA's Review of the ReGen Menaflex


Accessibility Information

Persons with disabilities having problems accessing the Attachment may contact Tina Gilliam, 301-796-5217 for assistance.

 

 

    
-
-
-
-
-